[{"address1": "400 Spectrum Center Drive", "address2": "Suite 2040", "city": "Irvine", "state": "CA", "zip": "92618", "country": "United States", "phone": "949 409 3700", "website": "https://cgoncology.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy that is in phase 3 clinical trial for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008, which is in phase 2 clinical trial for treating patients with high-risk NMIBC, including BCG-exposed and BCG-na\u00efve NMIBC patients. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.", "fullTimeEmployees": 113, "companyOfficers": [{"maxAge": 1, "name": "Mr. Arthur  Kuan", "age": 34, "title": "Chairman & CEO", "yearBorn": 1991, "fiscalYear": 2024, "totalPay": 1037565, "exercisedValue": 0, "unexercisedValue": 11551042}, {"maxAge": 1, "name": "Mr. Ambaw  Bellete M.S.", "age": 54, "title": "President & COO", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 769967, "exercisedValue": 0, "unexercisedValue": 6379648}, {"maxAge": 1, "name": "Mr. James M. DeTore", "age": 60, "title": "Interim Principal Financial & Accounting Officer", "yearBorn": 1965, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Swapnil  Bhargava Ph.D.", "title": "Chief Technical Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Amy  Steele", "title": "Vice President of Finance & Administration", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joshua F. Patterson", "age": 49, "title": "General Counsel, Chief Compliance Officer & Secretary", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sarah  Connors", "title": "Vice President of Communications & Patient Advocacy", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bing  Kung", "title": "Vice President of Corporate Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vijay  Kasturi M.D.", "age": 57, "title": "Chief Medical Officer", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 299688, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1768176000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 53.07, "open": 53.2, "dayLow": 52.17, "dayHigh": 55.17, "regularMarketPreviousClose": 53.07, "regularMarketOpen": 53.2, "regularMarketDayLow": 52.17, "regularMarketDayHigh": 55.17, "payoutRatio": 0.0, "forwardPE": -21.72679, "volume": 994831, "regularMarketVolume": 994831, "averageVolume": 1003952, "averageVolume10days": 1707370, "averageDailyVolume10Day": 1707370, "bid": 39.08, "ask": 67.36, "bidSize": 2, "askSize": 2, "marketCap": 4522027008, "fiftyTwoWeekLow": 14.8, "fiftyTwoWeekHigh": 57.395, "allTimeHigh": 57.395, "allTimeLow": 14.8, "priceToSalesTrailing12Months": 2080.0493, "fiftyDayAverage": 42.307, "twoHundredDayAverage": 32.39355, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 3741838080, "profitMargins": 0.0, "floatShares": 65435598, "sharesOutstanding": 82624285, "sharesShort": 12919357, "sharesShortPriorMonth": 13713699, "sharesShortPreviousMonthDate": 1764288000, "dateShortInterest": 1767139200, "sharesPercentSharesOut": 0.1602, "heldPercentInsiders": 0.0298, "heldPercentInstitutions": 1.10371, "shortRatio": 15.43, "shortPercentOfFloat": 0.1691, "impliedSharesOutstanding": 82624285, "bookValue": 8.785, "priceToBook": 6.2299376, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -151484000, "trailingEps": -2.05, "forwardEps": -2.51901, "enterpriseToRevenue": 1721.177, "enterpriseToEbitda": -20.843, "52WeekChange": 0.76900005, "SandP52WeekChange": 0.14799047, "quoteType": "EQUITY", "currentPrice": 54.73, "targetHighPrice": 108.0, "targetLowPrice": 55.0, "targetMeanPrice": 76.57143, "targetMedianPrice": 76.0, "recommendationMean": 1.26667, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 14, "totalCash": 680262976, "totalCashPerShare": 8.433, "ebitda": -179527008, "totalDebt": 7241000, "quickRatio": 22.3, "currentRatio": 22.792, "totalRevenue": 2174000, "debtToEquity": 1.053, "revenuePerShare": 0.029, "returnOnAssets": -0.17557, "returnOnEquity": -0.24744, "grossProfits": -112886000, "freeCashflow": -77783872, "operatingCashflow": -116792000, "revenueGrowth": 37.744, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -30.68968, "financialCurrency": "USD", "symbol": "CGON", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1768602173, "regularMarketTime": 1768597200, "exchange": "NMS", "regularMarketChangePercent": 3.12794, "regularMarketPrice": 54.73, "shortName": "CG Oncology, Inc.", "longName": "CG Oncology, Inc.", "marketState": "CLOSED", "messageBoardId": "finmb_115902660", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1706193000000, "postMarketChangePercent": 0.0, "postMarketPrice": 54.73, "postMarketChange": 0.0, "regularMarketChange": 1.66, "regularMarketDayRange": "52.17 - 55.17", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1003952, "fiftyTwoWeekLowChange": 39.93, "fiftyTwoWeekLowChangePercent": 2.697973, "fiftyTwoWeekRange": "14.8 - 57.395", "fiftyTwoWeekHighChange": -2.665001, "fiftyTwoWeekHighChangePercent": -0.046432633, "fiftyTwoWeekChangePercent": 76.90001, "earningsTimestamp": 1763127000, "earningsTimestampStart": 1763127000, "earningsTimestampEnd": 1763127000, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -2.05, "epsForward": -2.51901, "epsCurrentYear": -2.07763, "priceEpsCurrentYear": -26.342514, "fiftyDayAverageChange": 12.423, "fiftyDayAverageChangePercent": 0.29363936, "twoHundredDayAverageChange": 22.336449, "twoHundredDayAverageChangePercent": 0.6895338, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2024-01-25", "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "displayName": "CG Oncology", "trailingPegRatio": null, "__fetch_time": "2026-01-17"}]